OmicsGlioma - personalized therapy for brain tumos
The OmicsGlioma Consortium
Related publications of the consortium
Enam A, Kalasauskas D, Buzdin A, Kim E, Giese A. Molecularly-based diagnostics and individualized therapy of malignant brain tumors from a global perspective. under revision 2016
Barrantes-Freer A, Renovanz M, Pardo LA, Giese A, Kim EL. CD133 expression is not synonymous to immunoreactivity for AC133 and reflects the stage of cell cycle in glioma cells. PlosOne 18:10(6) e0130519, 2015
Buzdin AA, Zhavoronkov AA, Korzinkin MB, Venkova LS, Zenin AA, Smirnov PY, Borisov NM.
Lezhnina K, Kovalchuk O, Zhavoronkov AA, Korzinkin MB, Zabolotneva AA, Shegay PV, Sokov DG, Gaifullin NM, Rusakov IG, Aliper AM, Roumiantsev SA, Alekseev BY, Borisov NM, Buzdin AA. Novel robust biomarkers for human bladder cancer based on activation of intracellular signaling pathways. Oncotarget. 2014 5(19):9022-32.
Renovanz, M. and E.L. Kim, Intratumoral heterogeneity, its contribution to therapy resistance and methodological caveats to assessment. Molecular mechanisms of cellular stress responses in cancer and their therapeutic implications, Front Oncol 2014: p. 121
Spirin PV, Lebedev TD, Orlova NN, Gornostaeva AS, Prokofjeva MM, Nikitenko NA, Dmitriev SE, Buzdin AA, Borisov NM, Aliper AM, Garazha AV, Rubtsov PM, Stocking C, Prassolov VS. Silencing AML1-ETO gene expression leads to simultaneous activation of both pro-apoptotic and proliferation signaling. Leukemia. 2014 28(11):2222-8.
Barrantes-Freer A, Kim E, Bielanska J, Giese A, Mortensen LS, Schulz-Schaeffer WJ, Stadelmann C, Brück W, Pardo LA. Human glioma-initiating cells show a distinct immature phenotype resembling but not identical to NG2 glia. J Neuropathol Exp Neurol, 72:307-24, PMID: 23481707, 2013